Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

FHTX

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2024-09-23Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:44,346,059Shares Outstanding:69,540,075Institutional Ownership Pct.:63.77%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	68	88	81	89	73	61	55	58	139	79	80	70
Marketable Securities	100	96	78	91	126	160	188	210	146	127	154	190
Restricted Cash Current	0	1	1	1	1	-	0	-	-	-	-	-
Prepaid Expense And Other Assets Current	2	3	3	3	4	5	6	4	4	5	6	6
Assets Current	170	188	163	184	204	225	250	271	290	212	240	265
Property Plant And Equipment And Finance Lease Rig…	-	2	2	9	10	10	10	11	11	12	13	14
Restricted Cash Noncurrent	2	2	2	2	2	2	2	2	2	2	2	2
Other Assets Noncurrent	0	0	0	0	0	0	0	1	1	1	1	1
Operating Lease Right Of Use Asset	30	30	31	10	11	21	23	24	25	29	30	31
Assets	203	222	198	205	226	259	284	308	329	255	286	313
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	3	3	4	3	3	4	4	3	5	6	6	6
Accounts Payable And Other Accrued Liabilities Cur…	8	7	11	10	9	6	9	11	6	6	9	9
Operating Lease Liability Current	3	2	1	7	6	9	9	9	9	9	9	8
Contract With Customer Liability Current	37	52	43	65	60	52	46	33	31	32	35	28
Liabilities Current	51	64	60	85	78	71	67	57	51	52	58	52
Operating Lease Liability Noncurrent	40	40	40	16	18	26	28	30	28	34	37	39
Contract With Customer Liability Noncurrent	193	194	206	193	207	222	234	250	259	266	268	280
Other Liabilities Noncurrent	0	0	1	1	1	1	0	-	-	-	0	0
Liabilities	284	299	307	295	303	320	330	337	343	352	363	371
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	579	576	524	521	518	515	513	510	506	400	395	392
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	-0	0	0	0	-0	-0	-1	-2
Retained Earnings Accumulated Deficit	-660	-652	-632	-611	-595	-577	-558	-539	-520	-497	-472	-447
Stockholders Equity	-81	-76	-109	-90	-77	-62	-46	-28	-14	-97	-77	-57
Liabilities And Stockholders Equity	203	222	198	205	226	259	284	308	329	255	286	313
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	25	25	25	25	25	25	25	25	25	25	25	25
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	175	175	175	175	175	175	175	175	175	175	175	175
Common Stock Shares Issued	59	59	57	57	56	56	56	56	55	43	42	42
Shares Outstanding	59	59	57	57	56	56	56	56	55	43	42	42

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	1.90%	0.48%	15.48%	-	-	-	-	-	-	-	-	-
2025	8.52%	24.82%	21.41%	1.20%	-2.80%	-18.60%	18.75%	35.00%	47.00%	-12.74%	-15.75%	-24.25%
2024	0.00%	-1.37%	15.95%	58.02%	78.63%	47.33%	-3.03%	-41.50%	-50.73%	-21.78%	-3.11%	-8.00%
2023	-	-	-	-	-	-	10.66%	70.56%	-2.54%	-1.76%	-19.62%	-17.42%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	3.36	2.92	2.73	2.16	2.62	3.16	3.73	4.77	5.69	4.06	4.11	5.10
Quick Ratio	3.31	2.87	2.68	2.13	2.57	3.09	3.64	4.71	5.61	3.97	4.01	5.00
Working Capital	119.47M	123.66M	103.50M	99.03M	126.06M	154.11M	182.61M	214.41M	238.75M	159.46M	181.75M	213.43M
Leverage & Debt
Debt to Equity	-3.51	-3.91	-2.83	-3.29	-3.95	-5.20	-7.24	-11.90	-23.94	-3.62	-4.70	-6.46
Debt Ratio	1.40	1.34	1.55	1.44	1.34	1.24	1.16	1.09	1.04	1.38	1.27	1.18
Efficiency & Turnover
Asset Turnover TTM	0.17	0.12	0.13	0.10	0.09	0.09	0.08	0.08	0.11	0.11	0.10	0.09
Per Share Metrics
Diluted EPS TTM	-0.91	-1.08	-1.18	-1.14	-1.20	-1.28	-1.58	-1.46	-1.68	-2.19	-2.34	-2.46
Free Cash Flow Per Share TTM	-1.18	-1.26	-1.37	-1.03	-1.07	-1.53	-1.85	-1.66	-2.13	-2.76	-2.84	-2.88
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-198.04%	-301.34%	-279.49%	-352.87%	-380.04%	-414.41%	-454.31%	-408.14%	-276.72%	-303.23%	-315.93%	-351.04%
Net Profit Margin TTM	-175.78%	-266.88%	-240.33%	-294.16%	-311.90%	-342.23%	-383.24%	-357.53%	-245.69%	-274.23%	-288.17%	-316.87%
Growth Metrics
Net Revenue Growth (1Y)	51.98%	20.08%	36.75%	-3.91%	-31.30%	-30.66%	-33.83%	-21.66%	61.95%	64.41%	77.63%	106.70%
Net Income Growth (1Y)	-14.35%	-6.36%	-14.24%	-20.94%	-12.78%	-13.46%	-11.99%	-11.61%	-24.59%	-17.34%	-9.60%	-5.44%
EPS Growth (1Y)	-23.62%	-15.37%	-25.25%	-21.47%	-28.57%	-41.58%	-32.71%	-40.66%	-38.85%	-18.55%	-10.43%	-6.23%
Valuation Metrics
P/E TTM	-5.34	-4.41	-4.58	-4.27	-3.93	-2.85	-2.99	-6.39	-3.43	-3.06	-2.75	-2.04
P/B TTM	-4.25	-4.35	-3.13	-3.44	-3.86	-3.72	-5.69	-20.60	-20.71	-2.92	-3.51	-3.66
P/S TTM	9.38	11.78	11.00	12.57	12.24	9.76	11.46	22.84	8.43	8.40	7.93	6.45
Market Cap	344.67M	332.40M	340.10M	308.21M	296.00M	229.40M	259.13M	582.83M	296.59M	284.70M	270.74M	210.13M
Enterprise Value	274.59M	241.49M	255.97M	215.63M	220.18M	166.66M	203.67M	523.45M	155.93M	203.74M	188.69M	138.12M
Calculated Values
Free Cash Flow TTM	-83.02M	-87.43M	-86.16M	-64.89M	-67.35M	-95.86M	-101.31M	-103.89M	-109.87M	-116.96M	-119.33M	-120.95M
Net Debt	-70.08M	-90.91M	-84.13M	-92.58M	-75.82M	-62.73M	-55.45M	-59.39M	-140.66M	-80.96M	-82.04M	-72.01M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2024-09-23Sale

Owner: Costa, Carlos

Title: Chief People Officer

Shares: 857

Price/Share: $10.17

Value: $8,715.69

Shares Owned: -

Relationship: Officer

Ownership: Direct

2024-09-18Sale

Owner: Costa, Carlos

Title: Chief People Officer

Shares: 11,574

Price/Share: $10.05

Value: $116,318.70

Shares Owned: -

Relationship: Officer

Ownership: Direct

2024-09-17Sale

Owner: Costa, Carlos

Title: Chief People Officer

Shares: 10,272

Price/Share: $10.04

Value: $103,130.88

Shares Owned: -

Relationship: Officer

Ownership: Direct

2024-09-09Sale

Owner: Bellon, Steven F.

Title: Chief Scientific Officer

Shares: 20,000

Price/Share: $9.50

Value: $190,000.00

Shares Owned: 101,957

Relationship: Officer

Ownership: Direct

2024-03-11Sale

Owner: Cavalie, Fanny

Title: Chief Strategy/Bus Ops Officer

Shares: 11,000

Price/Share: $6.56

Value: $72,160.00

Shares Owned: 75,992

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2024-09-23	Costa, Carlos	Officer	Chief People Officer	Direct	Sale	857	10.17	$8,715.69	0	4
2024-09-18	Costa, Carlos	Officer	Chief People Officer	Direct	Sale	11,574	10.05	$116,318.70	0	4
2024-09-17	Costa, Carlos	Officer	Chief People Officer	Direct	Sale	10,272	10.04	$103,130.88	0	4
2024-09-09	Bellon, Steven F.	Officer	Chief Scientific Officer	Direct	Sale	20,000	9.50	$190,000.00	101,957	4
2024-03-11	Cavalie, Fanny	Officer	Chief Strategy/Bus Ops Officer	Direct	Sale	11,000	6.56	$72,160.00	75,992	4
2023-08-16	Agresta, Samuel	Officer	Chief Medical Officer	Direct	Sale	311,297	8.25	$2,568,200.25	0	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

63.77%

Inst. Shares: 44,346,059

Shares Outstanding: 69,540,075

2025-12-31

66.42%

Inst. Shares: 41,834,727

Shares Outstanding: 62,980,959

2025-09-30

64.86%

Inst. Shares: 40,881,869

Shares Outstanding: 63,029,293

2025-06-30

64.89%

Inst. Shares: 40,868,700

Shares Outstanding: 62,978,219

2025-03-31

64.18%

Inst. Shares: 40,338,209

Shares Outstanding: 62,848,673

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	44,346,059	69,540,075	63.77%
2025-12-31	41,834,727	62,980,959	66.42%
2025-09-30	40,881,869	63,029,293	64.86%
2025-06-30	40,868,700	62,978,219	64.89%
2025-03-31	40,338,209	62,848,673	64.18%
2024-12-31	40,131,273	54,899,432	73.10%
2024-09-30	39,900,621	62,602,848	63.74%
2024-06-30	39,168,894	51,580,310	75.94%
2024-03-31	26,262,425	42,428,813	61.90%
2023-12-31	25,385,712	41,974,484	60.48%
2023-09-30	25,087,945	42,025,938	59.70%
2023-06-30	24,926,796	41,825,555	59.60%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Foghorn Therapeutics Inc. (FHTX) — SEC Financial Statements & Analysis

Foghorn Therapeutics Inc. (FHTX) is a pharmaceutical preparations company, incorporated in DE. Foghorn Therapeutics Inc. trades on Nasdaq as: FHTX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Foghorn Therapeutics Inc. reported a 51.98% year-over-year revenue growth, a Debt-to-Equity ratio of -3.51x, a Price-to-Sales (P/S) ratio of 9.38x (TTM), a Price-to-Book (P/B) ratio of -4.25x (TTM), at a market cap of $344.67M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 51.98%
Debt To Equity: -3.51x
P/S TTM: 9.38x
P/B TTM: -4.25x
Market Cap: $344.67M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Foghorn Therapeutics Inc. in?

Foghorn Therapeutics Inc. (FHTX) operates in the Pharmaceutical Preparations industry.

What is FHTX's market cap?

Foghorn Therapeutics Inc. (FHTX) has a market capitalization of $344.67M as of 2026-06-30.

What exchange does FHTX trade on?

Foghorn Therapeutics Inc. (FHTX) trades on the Nasdaq.

Where is Foghorn Therapeutics Inc. incorporated?

Foghorn Therapeutics Inc. is incorporated in DE.